About Dashenlin Pharmaceutical Group
Dashenlin Pharmaceutical Group is a publicly listed company based in Guangzhou (China) founded in 1999. A diversified range of generic drugs is manufactured in China. Its website dslyy.com draws about 27 thousand monthly visits. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.
Company details
Dashenlin Pharmaceutical Group was established in 1999 and is headquartered in Guangzhou, China. Operations are focused on the pharmaceutical sector, where diversified generic drugs are produced for multiple therapeutic categories. Manufacturing processes are conducted to meet regulatory standards in the generics industry. The companys online presence is maintained through dslyy.com, supporting distribution and information access across domestic and potential international markets.
- Headquarters Guangzhou, China
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website dslyy.com
- Legal Name Dashenlin Pharmaceutical Group Co., Ltd. Class A
- Annual Revenue$3.93 B (USD)3.8as on Dec 31, 2025
- Net Profit$177.12 M (USD)35.04as on Dec 31, 2025
- EBITDA$545.63 M (USD)11.54as on Dec 31, 2025
IPO & Listings of Dashenlin Pharmaceutical Group
Dashenlin Pharmaceutical Group is a publicly listed company on the SSE with ticker symbol 603233 in China, operating in the Retail trade sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 Jul 2017
- Listed onSSE: 603233
- Listed entityDaShenLin Pharmaceutical Group Co., Ltd. Class A
- Exchange sectorRetail trade
- ISINCNE100002RG2
- Share price18.99 CNY (+0.26% on the day) · 2026-10-14
- Market capitalisation21,518,788,422.00 CNY
- Price to earnings15.8
- EPS (diluted, trailing year)1.20 CNY
- Dividend yield4.38%
- Volume (last session)14,142,196
Financials of Dashenlin Pharmaceutical Group
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 27.50B CNY | 1.24B CNY | 3.82B CNY |
| 2024 | 26.50B CNY | 914.8M CNY | 3.42B CNY |
| 2023 | 24.53B CNY | 1.17B CNY | 3.47B CNY |
| 2022 | 21.25B CNY | 1.04B CNY | 3.11B CNY |
| 2021 | 16.69B CNY | 791.2M CNY | 2.46B CNY |
Detailed financial statements for Dashenlin Pharmaceutical Group
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Dashenlin Pharmaceutical Group
The website of Dashenlin Pharmaceutical Group (dslyy.com) receives about 26.6K visits a month.
- Monthly visits26.6K
▼ 51.2% vs previous month
Websites whose visitors overlap most with Dashenlin Pharmaceutical Group. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
800pharm.com | 800pharm.com | 100% | – | ||
lbxcn.com | lbxcn.com | 99% | #447,080 | – | |
360kxr.com | 360kxr.com | 98% | – | ||
ypk.39.net | ypk.39.net | 98% | – | ||
yaofang.cn | yaofang.cn | 79% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Dashenlin Pharmaceutical Group
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dashenlin Pharmaceutical Group
Complete news archive for Dashenlin Pharmaceutical Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dashenlin Pharmaceutical Group
Dashenlin Pharmaceutical Group was founded in 1999.
Dashenlin Pharmaceutical Group is headquartered in Guangzhou, China. It is registered at Guangzhou, Guangdong, China.
Annual revenue of Dashenlin Pharmaceutical Group is $3.93B as on Dec 31, 2025.
Dashenlin Pharmaceutical Group was established in 1999 and is headquartered in Guangzhou, China. Operations are focused on the pharmaceutical sector, where diversified generic drugs are produced for multiple therapeutic categories. Manufacturing processes are conducted to meet regulatory standards in the generics industry. The companys online presence is maintained through dslyy.com, supporting distribution and information access across domestic and potential international markets.
Yes, Dashenlin Pharmaceutical Group is publicly traded on SSE under the ticker symbol 603233.